natgillin/translations-raw huggingface dataset:
Insulin Human Winthrop Comb 30 100 IU/ml suspension for injection in a vial Insulin human
Insulin Human Winthrop Comb 30 100 IU/ml suspenzija za injekciju u bočici humani inzulin
Insulin Human Winthrop Comb 30 100 IU/ml suspension for injection Insulin human
Insulin Human Winthrop Comb 30 100 IU/ml suspenzija za injekciju humani inzulin
Insulin Human Winthrop Comb 30 must also not be mixed with insulins of animal origin or with insulin analogues.
Insulin Human Winthrop Comb 30 ne smije se miješati ni s inzulinima životinjskog podrijetla niti inzulinskim analozima.
Insulin Human Winthrop Comb 30 must not be administered intravenously and must not be used in infusion pumps or external or implanted insulin pumps.
Insulin Human Winthrop Comb 30 ne smije se primijeniti intravenski i ne smije se primjenjivati u infuzijskim pumpama niti u vanjskim ili ugrađenim inzulinskim pumpama.
Insulin Human Winthrop Comb 30 must not be mixed with any other insulin or with insulin analogues.
Insulin Human Winthrop Comb 30 ne smije se miješati ni s inzulinima životinjskog podrijetla niti s inzulinskim analozima.
Insulin Human Winthrop Comb 30 must not be used if this cannot be achieved, i.e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulin Human Winthrop Comb 30 ne smije se upotrijebiti ako se to ne može postići, tj. ako suspenzija, primjerice, ostane bistra ili ako se u inzulinu nalaze grudice, čestice ili pahuljice koje se mogu slijepiti za stijenke ili dno uloška.
Insulin Human Winthrop Comb 30 must not be used if this cannot be achieved, i.e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulin Human Winthrop Comb 30 se ne smije upotrijebiti ako se to ne može postići, tj. ako suspenzija, primjerice, ostane bistra ili ako se u inzulinu nalaze grudice, čestice ili pahuljice koje se mogu slijepiti za stijenke ili dno uloška.
Insulin Human Winthrop Comb 30 SoloStar 100 IU/ml suspension for injection in a pre-filled pen.
Insulin Human Winthrop Comb 30 SoloStar 100 IU/ml suspenzija za injekciju u napunjenoj brizgalici
Insulin Human Winthrop Comb 30 SoloStar 100 IU/ml suspension for injection Insulin human
Insulin Human Winthrop Comb 30 SoloStar 100 IU/ml suspenzija za injekciju humani inzulin
Insulin Human Winthrop Comb 50 100 IU/ml suspension for injection in a cartridge
Insulin Human Winthrop Comb 50 100 IU/ml suspenzija za injekciju u ulošku
Insulin Human Winthrop Comb 50 100 IU/ml suspension for injection in a cartridge Insulin human
Insulin Human Winthrop Comb 50 100 IU/ml suspenzija za injekciju u ulošku humani inzulin
Insulin Human Winthrop Comb 50 100 IU/ml suspension for injection in a vial
Insulin Human Winthrop Comb 50 100 IU/ml suspenzija za injekciju u bočici
Insulin Human Winthrop Comb 50 100 IU/ml suspension for injection in a vial Insulin human
Insulin Human Winthrop Comb 50 100 IU/ml suspenzija za injekciju u bočici humani inzulin
Insulin Human Winthrop Comb 50 100 IU/ml suspension for injection Insulin human
Insulin Human Winthrop Comb 50 100 IU/ml suspenzija za injekciju humani inzulin
Insulin Human Winthrop Comb 50 40 IU/ml suspension for injection in a vial
Insulin Human Winthrop Comb 50 40 IU/ml suspenzija za injekciju u bočici
Insulin Human Winthrop Comb 50 40 IU/ml suspension for injection in a vial Insulin human
Insulin Human Winthrop Comb 50 40 IU/ml suspenzija za injekciju u bočici humani inzulin
Insulin Human Winthrop Comb 50 40 IU/ml suspension for injection Insulin human
Insulin Human Winthrop Comb 50 40 IU/ml suspenzija za injekciju humani inzulin
Insulin Human Winthrop Comb 50 may be mixed with all insulin human formulations, but notwith those designed specifically for use in insulin pumps.
Insulin Human Winthrop Comb 50 može se miješati sa svim formulacijama humanog inzulina, ali ne i s onima koji su posebno namijenjeni za primjenu u inzulinskim pumpama.
Insulin Human Winthrop Comb 50 must not be administered intravenously and must not be used in infusion pumps or external or implanted insulin pumps.
Insulin Human Winthrop Comb 50 ne smije se primijeniti intravenski i ne smije se primjenjivati u infuzijskim pumpama niti u vanjskim ili ugrađenim inzulinskim pumpama.
Insulin Human Winthrop Comb 50 must not be used if this cannot be achieved, i.e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulin Human Winthrop Comb 50 ne smije se upotrijebiti ako se to ne može postići, tj. ako suspenzija, primjerice, ostane bistra ili ako se u inzulinu nalaze grudice, čestice ili pahuljice koje se mogu slijepiti za stijenke ili dno uloška.
Insulin Human Winthrop Comb 50 must not be used if this cannot be achieved, i.e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulin Human Winthrop Comb 50 se ne smije upotrijebiti ako se to ne može postići, tj. ako suspenzija, primjerice, ostane bistra ili ako se u inzulinu nalaze grudice, čestice ili pahuljice koje se mogu slijepiti za stijenke ili dno uloška.
Insulin Human Winthrop Comb 50 must not be used if this cannot be achieved, i.e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the vial.
Insulin Human Winthrop Comb 50 ne smije se upotrijebiti ako se to ne može postići, tj. ako suspenzija, primjerice, ostane bistra ili ako se u inzulinu nalaze grudice, čestice ili pahuljice koje se mogu slijepiti za stijenke ili dno bočice.
Insulin Human Winthrop Comb 50 SoloStar 100 IU/ml suspension for injection in a pre-filled pen.
Insulin Human Winthrop Comb 50 SoloStar 100 IU/ml suspenzija za injekciju u napunjenoj brizgalici
Insulin Human Winthrop Infusat 100 IU/ml solution for injection in a cartridge
Insulin Human Winthrop Infusat 100 IU/ml otopina za injekciju u ulošku
Insulin Human Winthrop Infusat 100 IU/ml solution for injection in a vial
Insulin Human Winthrop Infusat 100 IU/ml otopina za injekciju u bočici
Insulin Human Winthrop Infusat is a clear, colourless solution for injection, with no solid particles visible, and of water-like consistency.
Insulin Human Winthrop Infusat je bistra, bezbojna, vodenasta otopina za injekciju koja ne sadrži vidljive krute čestice.
Insulin Human Winthrop Infusat is a solution to be given under the skin.
Insulin Human Winthrop Infusat je tekućina (otopina) za injekciju koja se daje pod kožu.
Insulin Human Winthrop Infusat is an insulin with rapid onset and short duration of action.
Insulin Human Winthrop Infusat je inzulin s brzim početkom i kratkim trajanjem djelovanja.
Insulin Human Winthrop Infusat must not be mixed with any other insulin or with insulin analogues.
Insulin Human Winthrop Infusat se ne smije miješati s drugim inzulinima niti inzulinskim analozima.
Insulin Human Winthrop Infusat must not be used in peristaltic pumps with silicone tubing.
Insulin Human Winthrop Infusat ne smije se primjenjivati u peristaltičkim pumpama sa silikonskim cijevima.
Insulin Human Winthrop Infusat must only be used if the solution is clear, colourless, with no solid particles visible, and has a water-like consistency.
Insulin Human Winthrop Infusat smije se upotrijebiti samo ako je otopina bistra, bezbojna, vodenasta i ako u njoj nema vidljivih krutih čestica.
Insulin Human Winthrop Infusat must only be used if the solution is clear, colourless, with no solid particles visible, and if it is of a water-like consistency.
Insulin Human Winthrop Infusat smije se koristiti samo ako je otopina bistra, bezbojna, vodenasta i ako nema vidljivih krutih čestica.
Insulin Human Winthrop Rapid 100 IU/ml solution for injection in a cartridge
Insulin Human Winthrop Rapid 100 IU/ml otopina za injekciju u ulošku
Insulin Human Winthrop Rapid 100 IU/ml solution for injection in a vial
Insulin Human Winthrop Rapid 100 IU/ml otopina za injekciju u bočici
Insulin Human Winthrop Rapid 40 IU/ml solution for injection in a vial
Insulin Human Winthrop Rapid 40 IU/ml otopina za injekciju u bočici
Insulin Human Winthrop Rapid alcohol
Insulin Human Winthrop Rapid s alkoholom
Insulin Human Winthrop Rapid can be used during breast-feeding.
Insulin Human Winthrop Infusat može se primjenjivati tijekom dojenja.
Insulin Human Winthrop Rapid is a clear, colourless solution for injection, with no solid particles visible, and of a water-like consistency.
Insulin Human Winthrop Rapid je bistra, bezbojna, vodenasta otopina za injekciju koja ne sadrži vidljive krute čestice.
Insulin Human Winthrop Rapid may be mixed with all insulin human formulations, but not with those designed specifically for use in insulin pumps
Insulin Human Winthrop Rapid može se miješati sa svim formulacijama humanog inzulina, ali ne i s onima koji su posebno namijenjeni za primjenu u inzulinskim pumpama.
Insulin Human Winthrop Rapid may be mixed with all insulin human formulations, but not with those designed specifically for use in insulin pumps.
Insulin Human Winthrop Rapid može se miješati sa svim formulacijama humanog inzulina, ali ne i s onima koji su posebno namijenjeni za primjenu u inzulinskim pumpama.
Insulin Human Winthrop Rapid must also not be mixed with insulins of animal origin or with insulin analogues.
Insulin Human Winthrop Rapid se ne smije miješati ni s inzulinima životinjskog podrijetla niti inzulinskim analozima.
Insulin Human Winthrop Rapid must not be mixed with any other insulin or with insulin analogues.
Insulin Human Winthrop Rapid se ne smije miješati s drugim inzulinima niti inzulinskim analozima.
Insulin Human Winthrop Rapid must only be used if the solution is clear, colourless, with no solid particles visible, and has a water-like consistency.
Insulin Human Winthrop Rapid smije se upotrijebiti samo ako je otopina bistra, bezbojna, vodenasta i ako u njoj nema vidljivih krutih čestica.
Insulin Human Winthrop Rapid must only be used if the solution is clear, colourless, with no solid particles visible, and if it is of a water-like consistency.
Insulin Human Winthrop Rapid smije se koristiti samo ako je otopina bistra, bezbojna, vodenasta i ako nema vidljivih krutih čestica.
Insulin Human Winthrop Rapid SoloStar 100 IU/ml solution for injection in a pre-filled pen Insulin human
Insulin Human Winthrop Rapid SoloStar 100 IU/ml otopina za injekciju u napunjenoj brizgalici humani inzulin
Insulin Human Winthrop Rapid SoloStar 100 IU/ml solution for injection in a pre-filled pen.
Insulin Human Winthrop Rapid SoloStar 100 IU/ml otopina za injekciju u napunjenoj brizgalici
Insulin Human Winthrop Rapid SoloStar 100 IU/ml solution for injection Insulin human
Insulin Human Winthrop Rapid SoloStar 100 IU/ml otopina za injekciju humani inzulin
Insulin Human Winthrop Rapid”), hydrochloric acid (for pH adjustment) and water for injections.
"Važne informacije o nekim sastojcima lijeka Insulin Human Winthrop Rapid"), kloridna kiselina (za podešavanje pH) i voda za injekcije.
Insulin human* 40 IU as protamine zinc insulin.
Ljudski inzulin* 40 IU u obliku protamin-cink inzulina
Insulin is a substance produced by the pancreas.
Inzulin je tvar koju proizvodi gušterača.
Insulin is leaking from the pen.
Inzulin istječe iz brizgalice.
Insulin label must always be checked before each administration to avoid medication errors between Insuman Implantable and other insulins (see section 6.6).
Prije svake primjene uvijek se mora provjeriti naljepnica na inzulinu kako ne bi došlo do medikacijskih pogrešaka u primjeni zbog zamjene lijeka Insuman Implantable i drugih inzulina (vidjeti dio 6.6).
Insulin label must always be checked before each injection to avoid medication errors between insulin glulisine and other insulins (see section 4.4).
Prije svake injekcije mora se provjeriti naljepnica na inzulinu kako ne bi došlo do pogrešaka u primjeni zbog zamjene inzulina glulizina i drugih inzulina (vidjeti dio 4.4).
Insulin lispro (rDNA origin)
inzulin lispro (dobiven tehnologijom rekombinantne DNK)
Insulin lispro 200 units/ml solution for injection was bioequivalent to insulin lispro 100 units/ml solution for injection after subcutaneous administration of a single 20 unit dose in healthy subjects.
Nakon supkutane primjene jednokratne doze od 20 jedinica u zdravih ispitanika, otopina inzulina lispro za injekciju od 200 jedinica/ml bila je bioekvivalentna otopini inzulina lispro za injekciju od 100 jedinica/ml.
Insulin lispro did not induce fertility impairment in animal studies (see section 5.3).
U ispitivanjima na životinjama inzulin lispro nije uzrokovao poremećaj plodnosti (vidjeti dio 5.3).
Insulin lispro has a rapid onset of action (approximately 15 minutes), thus allowing it to be given closer to a meal (within zero to 15 minutes of the meal) when compared to regular insulin (30 to 45 minutes before).
Inzulin lispro počinje djelovati brzo (za približno 15 minuta), što omogućuje primjenu bliže obroku (u roku od 15 minuta prije ili nakon obroka) u usporedbi s običnim inzulinom (30 do 45 minuta prije obroka).
Insulin lispro is available as Humalog in the soluble form, which acts more or less immediately after injection, and as Humalog Basal in the ‘protamine suspension’ form, which is absorbed much more slowly so that it works for longer.
Inzulin lispro dostupan je kao Humalog u topivom obliku, koji djeluje više ili manje neposredno nakon ubrizgavanja, te kao Humalog Basal u obliku „suspenzije protamina“, koji se apsorbira mnogo sporije tako da dulje djeluje.
Insulin lispro is available as Liprolog in the soluble form, which acts more or less immediately after injection, and as Liprolog Basal in the ‘protamine suspension’ form, which is absorbed much more slowly so that it works for longer.
Inzulin lispro dostupan je kao Liprolog u topivom obliku, koji djeluje više ili manje neposredno nakon ubrizgavanja, te kao Liprolog Basal u obliku „suspenzije protamina“, koji se apsorbira mnogo sporije tako da dulje djeluje.
Insulin lispro is closely related to human insulin which is a natural hormone made by the pancreas.
Inzulin lispro je vrlo sličan ljudskom inzulinu, prirodnom hormonu koji luči gušterača.
Insulin lispro is made in the laboratory by a ‘recombinant DNA technology’ process.
Inzulin lispro se proizvodi u laboratoriju 'tehnologijom rekombinantne DNK'.
Insulin lispro maintains more rapid absorption and elimination when compared to soluble human insulin in patients with hepatic impairment.
U bolesnika s oštećenjem jetre inzulin lispro se apsorbira i eliminira brže nego topljivi humani inzulin.
Insulin lispro maintains more rapid absorption when compared to soluble human insulin in patients with renal impairment.
U bolesnika s oštećenjem bubrega inzulin lispro se apsorbira brže nego topljivi humani inzulin.
Insulin lispro takes effect rapidly and has a shorter duration of activity (2 to 5 hours) when compared to regular insulin.
Učinak inzulina lispro nastupa brzo i traje kraće (2 do 5 sati) u usporedbi s običnim inzulinom.
Insulin mix-ups
Primjena pogrešnog inzulina
Insulin requirements may be increased by medicinal products with hyperglycaemic activity, such as oral contraceptives, corticosteroids, or thyroid replacement therapy, danazol, beta2 stimulants (such as ritodrine, salbutamol, terbutaline).
Bolesnikovu potrebu za inzulinom mogu povećati lijekovi koji djeluju hiperglikemijski, primjerice oralni kontraceptivi, kortikosteroidi, zamjenski hormoni štitnjače, danazol, agonisti beta-2 receptora (poput ritodrina, salbutamola ili terbutalina).
Insulin requirements may be increased by substances with hyperglycaemic activity, such as oral contraceptives, corticosteroids, or thyroid replacement therapy, danazol, beta2 stimulants (such as ritodrine, salbutamol, terbutaline).
Bolesnikovu potrebu za inzulinom mogu povećati lijekovi koji djeluju hiperglikemijski, primjerice oralni kontraceptivi, kortikosteroidi, zamjenski hormoni štitnjače, danazol, agonisti beta-2 receptora (poput ritodrina, salbutamola ili terbutalina).
Insulin requirements may be reduced in the presence of medicinal products with hypoglycaemic activity, such as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulpha antibiotics, certain antidepressants (monoamine oxidase inhibitors, selective serotonin reuptake inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta-blockers, octreotide or alcohol.
Bolesnikova potreba za inzulinom može se smanjiti kod istodobne primjene lijekova koji djeluju hipoglikemijski, kao što su oralni antidijabetici, salicilati (npr. acetilsalicilatna kiselina), sulfonamidni antibiotici, neki antidepresivi (inhibitori monoaminooksidaze, selektivni inhibitori ponovne pohrane serotonina), neki inhibitori angiotenzin konvertirajućeg enzima (kaptopril, enalapril), blokatori receptora angiotenzina II, beta-blokatori, oktreotid i alkohol.
Insulin requirements may be reduced in the presence of medicinal products with hypoglycaemic activity, such as oral hypoglycemics, salicylates (for example, acetylsalicylic acid), sulpha antibiotics, certain antidepressants (monoamine oxidase inhibitors, selective serotonin reuptake inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta-blockers, octreotide or alcohol.
Bolesnikova potreba za inzulinom može se smanjiti kod istodobne primjene lijekova koji djeluju hipoglikemijski, kao što su oralni antidijabetici, salicilati (npr. acetilsalicilatna kiselina), sulfonamidni antibiotici, neki antidepresivi (inhibitori monoamino-oksidaze, selektivni inhibitori ponovne pohrane serotonina), neki inhibitori angiotenzin konvertirajućeg enzima (kaptopril, enalapril), blokatori receptora angiotenzina II, beta-blokatori, oktreotid i alkohol.
Insulin requirements may be reduced in the presence of renal impairment.
Potrebe za inzulinom mogu biti smanjene u slučaju oštećenja bubrega.
Insulin requirements may be reduced in the presence of substances with hypoglycaemic activity, such as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulpha antibiotics, certain antidepressants (monoamine oxidase inhibitors, selective serotonin reuptake inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta- blockers, octreotide or alcohol.
Bolesnikova potreba za inzulinom može se smanjiti kod istodobne primjene lijekova koji djeluju hipoglikemijski, kao što su oralni antidijabetici, salicilati (npr. acetilsalicilatna kiselina), sulfonamidni antibiotici, neki antidepresivi (inhibitori monoamino-oksidaze, selektivni inhibitori ponovne pohrane serotonina), neki inhibitori angiotenzin konvertirajućeg enzima (kaptopril, enalapril), blokatori receptora angiotenzina II, beta-blokatori, oktreotid i alkohol.
Insulin requirements may be reduced in the presence of substances with hypoglycaemic activity, such as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulpha antibiotics, certain antidepressants, (monoamine oxidase inhibitors, selective serotonin reuptake inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta- blockers, octreotide or alcohol.
Bolesnikova potreba za inzulinom može se smanjiti kod istodobne primjene lijekova koji djeluju hipoglikemijski, kao što su oralni antidijabetici, salicilati (npr. acetilsalicilatna kiselina), sulfonamidni antibiotici, neki antidepresivi (inhibitori monoamino-oksidaze, selektivni inhibitori ponovne pohrane serotonina), neki inhibitori angiotenzin konvertirajućeg enzima (kaptopril, enalapril), blokatori receptora angiotenzina II, beta-blokatori, oktreotid i alkohol.
Insulin requirements may be reduced in the presence of substances with hypoglycaemic activity, such as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulphate antibiotics, certain antidepressants (monoamine oxidase inhibitors, selective serotonin reuptake inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta- blockers, octreotide or alcohol.
Bolesnikova potreba za inzulinom može se smanjiti kod istodobne primjene lijekova koji djeluju hipoglikemijski, kao što su oralni antidijabetici, salicilati (npr. acetilsalicilatna kiselina), sulfonamidni antibiotici, neki antidepresivi (inhibitori monoamino-oksidaze, selektivni inhibitori ponovne pohrane serotonina), neki inhibitori angiotenzin konvertirajućeg enzima (kaptopril, enalapril), blokatori receptora angiotenzina II, beta-blokatori, oktreotid i alkohol.
Insulin requirements may be reduced in the presence of substances with hypoglycaemic activity, such as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulphate antibiotics, certain antidepressants (monoamine oxidase inhibitors, selective serotonin reuptake inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta- blockers, octreotide, or alcohol.
Bolesnikova potreba za inzulinom može se smanjiti kod istodobne primjene lijekova koji djeluju hipoglikemijski, kao što su oralni antidijabetici, salicilati (npr. acetilsalicilatna kiselina), sulfonamidni antibiotici, neki antidepresivi (inhibitori monoamino-oksidaze, selektivni inhibitori ponovne pohrane serotonina), neki inhibitori angiotenzin konvertirajućeg enzima (kaptopril, enalapril), blokatori receptora angiotenzina II, beta-blokatori, oktreotid i alkohol.
Insulin requirements usually decrease in the first trimester and increase subsequently during the second and third trimester.
Potrebe za inzulinom obično se smanjuju tijekom prvog tromjesečja te naknadno povećavaju u drugom i trećem tromjesečju trudnoće.
Insulin resistance*
inzulinska rezistencija
insulin resistance, dyslipidemia, acne
(npr. inzulinske rezistencije,
insulin resistance, dyslipidemia, acne
(npr., inzulinske rezistencije,
INSULIN SECRETAGOGUES
INZULINSKI SEKRETAGOG
INSULIN SECRETAGOGUES
INZULINSKI SEKRETAGOZI
Insulin secretion/beta-cell function
Lučenje inzulina/funkcija beta stanica
Insulin under-delivery
Primjena premale doze inzulina
Insulin users
Koriste inzulin
Insulin with a rapid onset and moderately long duration of action.
Inzulin s brzim početkom i srednjedugim trajanjem djelovanja.
Insulin with a rapid onset and short duration of action.
Inzulin s brzim početkom i kratkim trajanjem djelovanja.
insulin, metformin or other medicines to treat diabetes mellitus
inzulin, metformin ili drugi lijekovi za liječenje šećerne bolesti
insulin; metformin, liraglutide, vildagliptin, nateglinide (antidiabetic medicines).
inzulin; metformin, liraglutid, vildagliptin, nateglinid (antidijabetici).
Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting, ATC code: A10AD06.
Inzulini i analozi za injiciranje, srednjedugodjelujući ili dugodjelujući u kombinaciji s brzodjelujućim, ATK oznaka: A10AD06.
Insulins of different concentration (e.g.
Ne smiju se miješati inzulini različitih koncentracija (npr.
Insuman Basal 100 IU/ml suspension for injection in a cartridge
Insuman Basal 100 IU/ml suspenzija za injekciju u ulošku
Insuman Basal 100 IU/ml suspension for injection in a cartridge for OptiClik Insulin human
Insuman Basal 100 IU/ml suspenzija za injekciju u ulošku za OptiClik humani inzulin
Insuman Basal 100 IU/ml suspension for injection in a cartridge for OptiClik.
Insuman Basal 100 IU/ml suspenzija za injekciju u ulošku za OptiClik
Insuman Basal 100 IU/ml suspension for injection in a cartridge Insulin human
Insuman Basal 100 IU/ml suspenzija za injekciju u ulošku humani inzulin
Insuman Basal 100 IU/ml suspension for injection in a pre-filled pen Insulin human
Insuman Basal 100 IU/ml suspenzija za injekciju u napunjenoj brizgalici humani inzulin
Insuman Basal 100 IU/ml suspension for injection in a pre-filled pen.
Insuman Basal 100 IU/ml suspenzija za injekciju u napunjenoj brizgalici
Insuman Basal 100 IU/ml suspension for injection in a vial
Insuman Basal 100 IU/ml suspenzija za injekciju u bočici